A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

NCT07285148 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

253

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
EGFR Mutation
Metastatic Lung Cancer
MET Alteration

Interventions

DRUG: ANS014004 + PLB1004
DRUG: ANS014004 + Osimertinib

Sponsor

Beijing Pearl Biotechnology Limited Liability Company

Collaborators

[object Object]